PURPOSE: Affibody molecules represent a novel class of high-affinity agents for radionuclide tumour targeting. Fusion of the Affibody molecules with an albumin-binding domain (ABD) enables modification of the blood kinetics of the Affibody molecules and reduction of the renal dose. (177)Lu-CHX-A''-DTPA-ABD-(Z(HER2:342))(2), an anti-HER2 Affibody molecule-ABD fusion protein has earlier demonstrated promising results in treatment of HER2-expressing micro-xenografts in mice. The use of the in vivo generator (114m)In/(114)In as a label for ABD-fused Affibody molecules would create preconditions for efficient treatment of both micrometastases (due to conversion and Auger electrons of (114m)In) and bulky tumours (due to high-energy beta particles from the daughter nuclide (114)In). The goal of this study was to investigate if different chelators influence the biodistribution of ABD-(Z(HER2:342))(2) and to find an optimal chelator for attachment of (114m)In to the Affibody molecule-ABD fusion protein. METHODS: Isothiocyanate derivatives of Bz-DOTA and CHX-A''-DTPA were coupled to ABD-(Z(HER2:342))(2). The cellular processing of both conjugates was studied in vitro. The influence of chelators on the biodistribution was investigated in mice using double isotope ((114m)In and (111)In) labelling. RESULTS: The apparent affinity of CHX-A''-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. It was found that both conjugates were internalized by SKOV-3 cells. The use of CHX-A''-DTPA provided better cellular retention of the radioactivity, better tumour accumulation of radioactivity and better tumour to organ dose ratios than Bz-DOTA-ABD-(Z(HER2:342))(2). CONCLUSION: CHX-A''-DTPA is more suitable for (114m)In labelling of Affibody molecule-ABD fusion proteins for radionuclide therapy.
PURPOSE: Affibody molecules represent a novel class of high-affinity agents for radionuclide tumour targeting. Fusion of the Affibody molecules with an albumin-binding domain (ABD) enables modification of the blood kinetics of the Affibody molecules and reduction of the renal dose. (177)Lu-CHX-A''-DTPA-ABD-(Z(HER2:342))(2), an anti-HER2 Affibody molecule-ABD fusion protein has earlier demonstrated promising results in treatment of HER2-expressing micro-xenografts in mice. The use of the in vivo generator (114m)In/(114)In as a label for ABD-fused Affibody molecules would create preconditions for efficient treatment of both micrometastases (due to conversion and Auger electrons of (114m)In) and bulky tumours (due to high-energy beta particles from the daughter nuclide (114)In). The goal of this study was to investigate if different chelators influence the biodistribution of ABD-(Z(HER2:342))(2) and to find an optimal chelator for attachment of (114m)In to the Affibody molecule-ABD fusion protein. METHODS: Isothiocyanate derivatives of Bz-DOTA and CHX-A''-DTPA were coupled to ABD-(Z(HER2:342))(2). The cellular processing of both conjugates was studied in vitro. The influence of chelators on the biodistribution was investigated in mice using double isotope ((114m)In and (111)In) labelling. RESULTS: The apparent affinity of CHX-A''-DTPA-ABD-(Z(HER2:342))(2) and Bz-DOTA-ABD-(Z(HER2:342))(2) to the extracellular domain of HER2 was similar, 13.5 and 15.0 pM, respectively. It was found that both conjugates were internalized by SKOV-3 cells. The use of CHX-A''-DTPA provided better cellular retention of the radioactivity, better tumour accumulation of radioactivity and better tumour to organ dose ratios than Bz-DOTA-ABD-(Z(HER2:342))(2). CONCLUSION:CHX-A''-DTPA is more suitable for (114m)In labelling of Affibody molecule-ABD fusion proteins for radionuclide therapy.
Authors: Anna Orlova; Thuy Tran; Charles Widström; Torun Engfeldt; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: Int J Mol Med Date: 2007-09 Impact factor: 4.101
Authors: Vladimir Tolmachev; Anna Orlova; Fredrik Y Nilsson; Joachim Feldwisch; Anders Wennborg; Lars Abrahmsén Journal: Expert Opin Biol Ther Date: 2007-04 Impact factor: 4.388
Authors: Jaspreet Singh Jaggi; Surya V Seshan; Michael R McDevitt; George Sgouros; Elizabeth Hyjek; David A Scheinberg Journal: Int J Radiat Oncol Biol Phys Date: 2006-02-28 Impact factor: 7.038
Authors: Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg Journal: J Nucl Med Date: 2004-01 Impact factor: 10.057
Authors: M Aas; G Mardirossian; T W Griffin; A R Salimi; T Ito; H S Bushe; R W Atcher; J J Hines; A B Brill; D J Hnatowich Journal: J Nucl Biol Med Date: 1992 Jan-Mar
Authors: Claudia T Mendler; Lars Friedrich; Iina Laitinen; Martin Schlapschy; Markus Schwaiger; Hans-Jürgen Wester; Arne Skerra Journal: MAbs Date: 2015 Impact factor: 5.857
Authors: Oskar Vilhelmsson Timmermand; David Ulmert; Susan Evans-Axelsson; Kim Pettersson; Anders Bjartell; Hans Lilja; Sven-Erik Strand; Thuy A Tran Journal: EJNMMI Res Date: 2014-09-19 Impact factor: 3.138